Trial Profile
A Phase I/IIa, Dose-Ranging Trial to Evaluate Safety, Tolerability and Immunogenicity of INO-4800, a Prophylactic Vaccine Against SARS-CoV-2, Administered Intradermally Followed by Electroporation in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 19 Jul 2022
Price :
$35
*
At a glance
- Drugs INO 4800 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Therapeutic Use
- 14 Jul 2022 Status changed from recruiting to completed.
- 18 Aug 2020 Status changed from not yet recruiting to recruiting.
- 10 Aug 2020 According to an Inovio Pharmaceuticals media release, this trial is approved in South Korea.